Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies
Publication
, Conference
Muir, AJ; Jurkowski, C; Cooney, EL; Hillson, JL; Lataillade, M; Casullo, VM; Gray, T; Xu, D; Yogendran, L; Srinivasan, S
Published in: HEPATOLOGY
October 1, 2013
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2013
Volume
58
Start / End Page
744A / 745A
Location
Washington, DC
Publisher
WILEY-BLACKWELL
Conference Name
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Jurkowski, C., Cooney, E. L., Hillson, J. L., Lataillade, M., Casullo, V. M., … Srinivasan, S. (2013). Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies. In HEPATOLOGY (Vol. 58, pp. 744A-745A). Washington, DC: WILEY-BLACKWELL.
Muir, Andrew J., Claire Jurkowski, Elizabeth L. Cooney, Jan L. Hillson, Max Lataillade, Veronica Mas Casullo, Todd Gray, Dong Xu, Logesvaran Yogendran, and Subasree Srinivasan. “Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies.” In HEPATOLOGY, 58:744A-745A. WILEY-BLACKWELL, 2013.
Muir AJ, Jurkowski C, Cooney EL, Hillson JL, Lataillade M, Casullo VM, et al. Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies. In: HEPATOLOGY. WILEY-BLACKWELL; 2013. p. 744A-745A.
Muir, Andrew J., et al. “Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies.” HEPATOLOGY, vol. 58, WILEY-BLACKWELL, 2013, pp. 744A-745A.
Muir AJ, Jurkowski C, Cooney EL, Hillson JL, Lataillade M, Casullo VM, Gray T, Xu D, Yogendran L, Srinivasan S. Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies. HEPATOLOGY. WILEY-BLACKWELL; 2013. p. 744A-745A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2013
Volume
58
Start / End Page
744A / 745A
Location
Washington, DC
Publisher
WILEY-BLACKWELL
Conference Name
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics